Literature DB >> 9030909

Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor.

M Ojima1, Y Inada, Y Shibouta, T Wada, T Sanada, K Kubo, K Nishikawa.   

Abstract

The mechanisms of the insurmountable antagonism of 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]1H-benzimid azole -7-carboxylic acid, candesartan (CV-11974), an angiotensin AT1 receptor antagonist, on angiotensin II-induced rabbit aortic contraction were examined in contraction and binding studies. Preincubation of the rabbit aorta with CV-11974 (0.1 nM) for 30 min reduced the maximal contractile response to angiostensin II by approximately 50%. This insurmountable antagonism of CV-11974 was reversed in the presence of losartan (1 microM), a surmountable angiotensin AT1 receptor antagonist. The inhibitory effect of CV-11974 on angiotensin II-induced contraction persisted longer after washing than did that of losartan but was irreversible. Scatchard analysis of [3H]CV-11974 binding in bovine adrenal cortical membranes indicated the existence of a single class of binding sites (Kd = 7.4 nM). Competition binding studies using angiotensin II receptor agonists and antagonists have demonstrated that [3H[CV-11974 binding sites may be identical to angiotensin AT1 receptors. The dissociation rate of [3H]CV-11974 binding (t1/2 = 66 min) was 5 times slower than that of [125I]angiotensin II binding (t1/2 = 12 min). These results suggest that the insurmountable antagonism by CV-11974 is due to its slow dissociation from angiotensin AT1 receptors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9030909     DOI: 10.1016/s0014-2999(96)00837-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  23 in total

1.  Angiotensin-converting enzyme (ACE) inhibition attenuates insulin-like growth factor-I (IGF-I) induced cardiac fibroblast proliferation.

Authors:  M van Eickels; H Vetter; C Grohé
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

Review 2.  Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action.

Authors:  Georges Vauquelin; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

3.  Estimation of the dissociation rate of unlabelled ligand-receptor complexes by a 'two-step' competition binding approach.

Authors:  A Packeu; M Wennerberg; A Balendran; G Vauquelin
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 4.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

5.  Ligand-specific conformation of extracellular loop-2 in the angiotensin II type 1 receptor.

Authors:  Hamiyet Unal; Rajaganapathi Jagannathan; Manjunatha B Bhat; Sadashiva S Karnik
Journal:  J Biol Chem       Date:  2010-03-18       Impact factor: 5.157

6.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

7.  Effects of angiotensin II receptor blockade on proximal fluid uptake in the rat kidney.

Authors:  M L Smart; S Hiranyachattada; P J Harris
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

8.  Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors.

Authors:  P M Vanderheyden; F L Fierens; J P De Backer; N Fraeyman; G Vauquelin
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

Review 9.  Candesartan cilexetil. A review of its use in essential hypertension.

Authors:  K J McClellan; K L Goa
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

10.  Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension.

Authors:  S E Kjeldsen; J Stålhammar; P Hasvold; J Bodegard; U Olsson; D Russell
Journal:  J Hum Hypertens       Date:  2009-11-05       Impact factor: 3.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.